Indo Us Biotech Limited — Results, 29-05-2026: Integrated Filing- Financial

Indo US Bio-Tech has approved its financial results for the quarter and year ended March 31, 2026.

**Financial Performance:** Annual revenue grew 6.56% YoY to Rs 11.04 Cr, driven by Seed Cultivation & Trading. However, Q4 revenue saw a sharp 51.85% YoY decline to Rs 2.60 Cr.

**Profitability & EPS:** Annual net profit dropped 19.36% YoY to Rs 13.12 Cr, with EPS at Rs 6.54. Quarterly net profit also fell 46.47% YoY to Rs 1.97 Cr, with EPS at Rs 1.19.

**Key Trends:** Increased finance costs and a significant rise in inventories impacted profitability. Operating cash flow turned negative, with a Rs 12.50 Cr outflow for the year.

**Final Lens for Investors:** These results reflect mixed financial momentum, with annual growth overshadowed by quarterly declines and cash flow pressures.